Dermata Therapeutics Valuation
| DRMA Stock | USD 1.83 0.06 3.39% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Dermata Therapeutics shows a prevailing Real Value of $3.87 per share. The current price of the firm is $1.83. Our model computes the value of Dermata Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 11.77 %, shares owned by insiders of 45.17 %, and Current Valuation of 609.61 K as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Dermata Therapeutics' valuation include:
Undervalued
Today
Please note that Dermata Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Dermata Therapeutics is based on 3 months time horizon. Increasing Dermata Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dermata Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dermata Stock. However, Dermata Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.83 | Real 3.87 | Target 10.0 | Hype 1.76 | Naive 1.14 |
The real value of Dermata Stock, also known as its intrinsic value, is the underlying worth of Dermata Therapeutics Company, which is reflected in its stock price. It is based on Dermata Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Dermata Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Dermata Therapeutics helps investors to forecast how Dermata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dermata Therapeutics more accurately as focusing exclusively on Dermata Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Dermata Therapeutics' intrinsic value based on its ongoing forecasts of Dermata Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Dermata Therapeutics' closest peers. If more than one evaluation category is relevant for Dermata Therapeutics we suggest using both methods to arrive at a better estimate.
Dermata Therapeutics Cash |
|
Dermata Therapeutics Total Value Analysis
Dermata Therapeutics is currently expected to have valuation of 609.61 K with market capitalization of 5.85 M, debt of 1.97 M, and cash on hands of 10.63 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Dermata Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
609.61 K | 5.85 M | 1.97 M | 10.63 M |
Dermata Therapeutics Asset Utilization
One of the ways to look at asset utilization of Dermata is to check how much profit was generated for every dollar of assets it reports. Dermata Therapeutics shows a negative utilization of assets of -0.96 percent, losing $0.009646 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Dermata Therapeutics shows how discouraging it operates for each dollar spent on its assets.Dermata Therapeutics Profitability Analysis
Based on Dermata Therapeutics' profitability indicators, Dermata Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Dermata Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -1.7 M | Current Value -1.7 M | Quarterly Volatility 792.4 K |
For Dermata Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dermata Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Dermata Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Dermata Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Dermata Therapeutics over time as well as its relative position and ranking within its peers.
Dermata Therapeutics Earnings per Share Projection vs Actual
By analyzing Dermata Therapeutics' earnings estimates, investors can diagnose different trends across Dermata Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Dermata Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Dermata Therapeutics Ownership Allocation
Dermata Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Dermata Therapeutics Profitability Analysis
Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Dermata Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Dermata Therapeutics and how it compares across the competition.
About Dermata Therapeutics Valuation
The stock valuation mechanism determines Dermata Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Dermata Therapeutics. We calculate exposure to Dermata Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dermata Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | (370.30) | (388.81) |
Dermata Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Dermata Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Dermata we look at many different elements of the entity such as Dermata's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Dermata Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Dermata Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Dermata Therapeutics' worth.Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |